Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer

Journal of Surgical Research

Volumn 142, Issue 2, 2007, Pages 378-386

  Konduri, Srivani ^a   Schwarz, Margaret A ^a   Cafasso, Danielle ^a   Schwarz, Roderich E ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

androgen receptor; combination therapy; hormonal therapy; pancreatic cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BEVACIZUMAB; FLUTAMIDE; GEMCITABINE; SULFORHODAMINE B; TESTOSTERONE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CELL LINE, TUMOR; DEOXYCYTIDINE; DIHYDROTESTOSTERONE; DRUG THERAPY, COMBINATION; FLUTAMIDE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548772350     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.09.034     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA-Cancer J Clin 56 (2006) 106
2. Cameron J.L., Riall T.S., Coleman J., et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 244 (2006) 10
3. Fong Y., Gonen M., Rubin D., et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 242 (2005) 540
4. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403
5. Andren-Sandberg A., Hoem D., and Backman P.L. Other risk factors for pancreatic cancer: Hormonal aspects. Ann Oncol 10 Suppl 4 (1999) S131
6. Greenway B.A. Effect of flutamide on survival in patients with pancreatic cancer: Results of a prospective, randomized, double blind, placebo controlled trial. BMJ 316 (1998) 1935
7. Roy A.K., Tyagi R.K., Song C.S., et al. Androgen receptor: Structural domains and functional dynamics after ligand-receptor interaction. Ann NY Acad Sci 949 (2001) 44
8. Klotz L., and Schellhammer P. Combined androgen blockade: The case for bicalutamide. Clin Prostate Cancer 3 (2005) 215
9. Culig Z., Klocker H., Bartsch G., et al. Androgen receptors in prostate cancer. Endocr Relat Cancer 9 (2002) 155
10. Simard J., Luthy I., Guay J., et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44 (1986) 261
11. Corbishley T.P., Iqbal M.J., Wilkinson M.L., et al. Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 57 (1986) 1992
12. Targarona E.M., Pons M.D., Gonzalez G., et al. Is exocrine pancreatic cancer a hormone-dependent tumor?. A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepatogastroenterology 38 (1991) 165
13. Schwarz R.E., Donohue C.A., Sadava D., et al. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: Implications for monotherapy and combination treatment. Cancer Lett 189 (2003) 59
14. Schwarz R.E., and Schwarz M.A. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res 120 (2004) 64
15. Katsuno M., Adachi H., Doyu M., et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9 (2003) 768
16. Raghow S., Hooshdaran M.Z., Katiyar S., et al. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370
17. Greenway B.A. Androgen receptor-blocking agents: Potential role in pancreatic cancer. Drugs Aging 17 (2000) 161
18. Greenway B., Iqbal M.J., Johnson P.J., et al. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) 283 (1981) 751
19. Diaz-Sanchez V., Morimoto S., Morales A., et al. Androgen receptor in the rat pancreas: Genetic expression and steroid regulation. Pancreas 11 (1995) 241
20. Sumi C., Brinck-Johnsen T., and Longnecker D.S. Inhibition of a transplantable pancreatic carcinoma by castration and estradiol administration in rats. Cancer Res 49 (1989) 6687
21. Lhoste E.F., Roebuck B.D., Stern J.E., et al. Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat. Pancreas 2 (1987) 38
22. Sumi C., Longnecker D.S., Roebuck B.D., et al. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 49 (1989) 2332
23. Lhoste E.F., Roebuck B.D., Brinck-Johnsen T., et al. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats. Carcinogenesis 8 (1987) 699
24. Meijers M., Visser C.J., Klijn J.G., et al. Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters. Int J Pancreatol 11 (1992) 137
25. Siu T.O., and Kwan W.B. Hormones in chemotherapy for pancreatic cancer, chemoagents, or carriers?. In Vivo 3 (1989) 255
26. Selvan R.S., Metzgar R.S., and Petrow V. Growth modulatory effects of some 6-methylenic steroids on human and hamster pancreatic adenocarcinoma cells in vitro. Drug Des Discov 9 (1992) 119
27. Adsay N.V., Basturk O., Cheng J.D., et al. Ductal neoplasia of the pancreas: Nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 15 (2005) 254
28. Sharma J.J., Razvillas B., Stephens C.D., et al. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15 (1997) 361
29. Negi S.S., Agarwal A., and Chaudhary A. Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial. Invest New Drugs 24 (2006) 189
30. Corrie P., Mayer A., Shaw J., et al. Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients. Br J Cancer 87 (2002) 716
31. Keating J.J., Johnson P.J., Cochrane A.M., et al. A prospective randomized controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60 (1989) 789
32. Philip P.A., Carmichael J., Tonkin K., et al. Hormonal treatment of pancreatic carcinoma: A phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67 (1993) 379
33. Swarovsky B., Wolf M., Havemann K., et al. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Oncology 50 (1993) 226
34. Latil A., Bieche I., Vidaud D., et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61 (2001) 1919
35. Leav I., Lau K.M., Adams J.Y., et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159 (2001) 79
36. Benz C., Hollander C., and Miller B. Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46 (1986) 2276
37. Corbishley T.P., Iqbal M.J., Wilkinson M.L., et al. Circulating sex steroids and sex hormone binding globulin in pancreatic adenocarcinoma. Anticancer Res 6 (1986) 219